Sentences with phrase «year over its drug»

But the company was hit by regulatory and political scrutiny in the past year over its drug pricing and its relationship to a mail - order pharmacy, and its stock took a beating.

Not exact matches

While trafficking routes have changed over time, in recent years narco subs and other vessels leaving southwest Colombia or northwest Ecuador laden with drug cargos often head out in the Pacific, even around the Galapagos Islands, before turning north in an effort to skirt law enforcement closer to home — which may include underwater sensors in Colombian waters — as well as US - led interdiction efforts.

Striking advances in hepatitis C drug development over the past five years have made the infectious, liver - wasting viral disease a curable one — if you can afford the drugs.

Miller, chief investment officer at LMM, said he thinks the embattled drugmaker is «a completely different company» than the one that was under severe fire for jacking up drug prices, and could see returns of 25 percent to 30 percent per year over the next five years.

Mark Merritt, CEO of the Pharmaceutical Care Management Association (PCMA), a trade group representing the 10 largest traditional PBMs, says that while «drug prices have gone up more than we'd like» over the years, his members have saved employers 25 %.

Sarepta Therapeutics, which won a pioneering Food and Drug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatmeDrug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatmedrug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatments.

The Tories are committing $ 44.9 million over five years to expand the focus of the National Anti-Drug Strategy from illicit street drugs to prescription drug abuse as well.

The drug lobby has spent nearly $ 17 million in just over two and a half years to oppose new regulation in California.

According to Industry Canada, Big Pharma spends more than $ 1.3 billion a year on R&D — and many global drug makers are increasingly looking at Canada for top talent and a cost - competitive advantage over the United States.

He added that the media focuses on examples of individual drug price hikes, it has overlooked the fact that expense of drugs as a proportion of healthcare spending has remained «remarkably constant» over the years.

Walmsley, who took over a year ago, is focusing on rebuilding GSK's drug pipeline by overhauling research and appointing heavyweight outsiders, such as veteran Roche scientist Hal Barron.

And for 27 years, before he was elected sheriff, he presided over court cases — ones that increasingly involved the stories of lives undone by drugs and poverty, and of an opioid epidemic taking root.

Despite this threat, and looming competition from a new Gilead Sciences HIV drug, GSK sees growth strengthening over the next few years, helped by the roll - out of newer medicines.

Half a million people develop drug - resistant TB each year; a UK parliamentary group in 2015 projected it will kill 75 million and cost the world $ 16.7 trillion over the next 35 years.

Last year the drug industry spent over $ 100 million on those ubiquitous adverts featuring Moose et al..

A month earlier drugmaker ICN Pharmaceuticals actually pleaded guilty to one count of criminal fraud for intentionally misleading investors — over many years, it now seems — about the FDA approval status of its flagship drug, ribavirin.

In attacking Berkshire, Ackman was striking back after Buffett's business partner Charlie Munger last year called Valeant «deeply immoral» for its practice of raising drug prices, sparking a sort of long - distance feud over whose favorite stock was better.

The 32 - year - old CEO of Turing Pharmaceuticals became a target of widespread ire in September when he boosted the price of the toxoplasmosis treatment Daraprim by over 5,000 % after acquiring the drug in August.

While there is no precise data about how heroin production in Mexico has changed in recent years, evidence suggests the drug's cultivation, and competition between gangs over it, has risen in Mexico, and in Guerrero in particular.

S&P Capital IQ analyst Jeffrey Loo estimates that there are 10 to 12 drugs in development today that could each yield at least US$ 1 billion in sales over the next few years.

Big pharma has been a persistent villain in the public's consciousness over the past year in the wake of exorbitant drug price hikes, including on ancient medications.

The number of drug arrests has nearly tripled over the past 30 or so years.

With more than 250,000 drug - and alcohol - related deaths a year nationwide, our society's battle against substance abuse is far from over.

The copycat therapy, Erelzi, won't be able to hit the market for at least another year thanks to the ongoing patent spat between Novartis and Amgen over the drug (Amgen claims that Enbrel has IP protection through 2029).

Count all the money Valeant has spent on acquisitions as drug research, and suddenly it has spent 200 % of its revenue over the past five years on R&D.

The investors are frustrated that shares in Jazz, a $ 9 billion pharmaceutical company known for its narcolepsy drug Xyrem, have remained essentially flat over the past year.

JERUSALEM — Israeli generic drug maker Teva Pharmaceutical Industries on Thursday said first - quarter earnings surged over 80 percent and raised its outlook for the rest of the year, citing progress in an aggressive restructuring plan.

To illustrate the issue, over the past 20 years, the cost of a new drug per year of a patient's life has risen from $ 50,000 to $ 250,000 after adjusting for inflation, according to Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering, who also spoke at the conference.

Nearly a year after it clashed with the Food and Drug Administration over labeling on its dried fruit and nut bars, KIND has received approval to use the word «healthy» as part of its marketing.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

This is quite a big deal as Valeant bought Sprout Pharmaceuticals, the company behind the drug for a whopping $ 1 billion just over two years ago.

Since Marathon won an approval to treat a condition that afflicts fewer than 200,000 Americans per year and has a dearth of treatment options (rather than trying to become an also - ran in the saturated steroid therapy field), it has carte blanche over the drug's pricing.

Further, I showed that Pharma's IRR has followed a rapid and steady linear decline over 20 years, which is consistent with recent estimates from BCG and Deloitte, and can be fully explained by the Law of Diminishing Returns as a natural and unavoidable consequence of prioritizing a limited set of investment opportunities while each new drug raises the bar for the next.

He told a Senate committee last year that the cost of the two drugs alone drove a nearly $ 12 million increase in Ascension's spending over one year.

Meanwhile, Pfizer's Essential Health segment, which sells older, mostly off - patent drugs, saw its sales decline 10 % year over year, to $ 5.36 billion.

Looking at the portfolio, the company's Innovative Health segment, which sells newer, patent - protected drugs, contributed sales of $ 7.42 billion, representing growth of 5 % year over year.

Over the years, a number of anonymous websites have sprung up to allow users to use bitcoins to purchase drugs and other illicit products.

The drug raked in just over $ 16 billion last year.

New patients must take their daily dose at a dedicated clinic, racking up single «take - home» doses over months and years of satisfactory urinalysis results that signify they aren't taking other drugs.

Drug overdose deaths — originally from prescription opioids but increasingly now from heroin and fentanyl — have emerged as an increasingly grave social issue, steadily worsening over the past few years even as the economy improves.

Specialty pharmaceuticals have contributed substantially to the rise in the nation's drug costs over the last several years, and these costs are projected to increase by more than 65 % by the end of 2017.

Over the past three decades, the Tufts Center for the Study of Drug Development has estimated both the cost and the years it takes for companies to develop new medicines.

DOJ investigates more than a dozen generic drug companies over alleged price fixation for two - dozen drugs, based on two year long investigation

(Reuters)- Eli Lilly and Co (LLY.N) said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs.

Antares Pharma (ATRS)- The company possesses a strong pipeline of drug / device combination product candidates which provide better treatment options in a variety of disease settings - Xyosted could potentially be approved by September and should see significant adoption due to several advantages over current treatments (keep in mind global male hypogonadism market to exceed $ 3 billion within 10 years).

Conservative foundations, multinational oil companies and a prescription drug maker were the most frequent sponsors of more than 100 expense - paid educational seminars attended by federal judges over a 4 1/2 - year period, according to a Center for Public Integrity investigation.

Generally understood as a provision permitting companies to test or experiment with patented inventions prior to an FDA submission - such as a generic drug maker prior to submission of an ANDA - the provision's scope has expanded over the years.

The latter is particularly important as regulatory approval for new drugs hinges on accurate data, and public trust in the pharma industry has ebbed and flowed over the years as stories of fabricated results make headlines.

The analyst their cites the generic drug maker «s diversified business model and its ability to grow profit and sales over the next several years.

For instance, pharmaceutical giant Roche's recently introduced HIV - inhibitor drug, Fuzeon, costs just over $ 20,000 per year.